| Proposed Ticker: ADZA | 1240 Elko Drive | |
| Exchange: NASDAQ-National Market | Sunnyvale, California 94089 | |
| Industry: Manufacturing | (408) 745-0975 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 5/13/96 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 2,500,000 | Expenses: | $750,000 | |
| Secondary Shares: | 0 | Shs Out After: | 7,863,669 | |
| Manager | Tier | Phone |
| Prudential Securities Incorporated | Lead Manager | (212) 214-3000 |
| Needham & Company | Co-manager | (212) 371-8300 |
| Tucker Anthony Incorporated | Co-manager | (617) 725-2000 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $3.96 | $0.15 | $0.27 | Assets: | $1.86 |
| Net Income: | -$1.14 | -$1.08 | -$0.87 | Liabilities: | $1.19 |
| EPS: | -$0.16 | -$0.20 | -$0.16 | Equity: | $0.67 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Adeza Biomedical Corporation ("Adeza" or the "Company") develops and markets diagnostic products and services for women's reproductive health care. The Company's primary focus is the development and marketing of proprietary tests for the diagnosis of pregnancy-related and female reproductive disorders, including premature and late birth, preeclampsia, endometriosis and infertility. The Company believes its products and services will result in improved patient management, with a consequent reduction in both patient risk and overall costs. Adeza's goal is to become a global leader in the diagnosis and treatment of pregnancy-related and female reproductive disorders by designing, developing and marketing proprietary diagnostic tests and services for the women's reproductive health care market. In addition to the fFN ELISA Test, the Company is developing several other products for this market. The Company is preparing supplements to its PMA ("PMA Supplements") for the use of the fFN ELISA Test in assessing the likelihood of premature birth in asymptomatic. The Company has received an expedited premarket approval ("PMA") from the Food and Drug Administration ("FDA") to market its proprietary enzyme-linked immunosorbent assay ("ELISA") diagnostic (the "fFN ELISA Test") for use in women with symptoms of premature birth. The fFN ELISA Test is the only FDA-approved immunodiagnostic test for this disorder and represents a significant advance over currently used evaluation techniques. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund research and development, expand sales and marketing activities, fund clinical trials, repay outstanding indebtedness and for working capital and general corporate purposes |
©1996 IPO Data Systems, Inc. - All rights reserved.